Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05342974 · ClinicalTrials.gov registry record · Early Phase 1
Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT05342974 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 9 participants.
The verdict
NCT05342974, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-49 days of pregnancy will receive an oral dose of atorvastatin (80 mg) to swallow at the clinic as well as taking atorvastatin (80 mg) daily for six additional days, with a return to clinic on day 8 after initial visit to take a dose of misoprostol (800 mcg). Additionally, follow-up visits will occur on approximately days 3, 8 and 11 for a clinician to perform an ultrasound to see if the abortion is complete.
Interventions
- DRUG Misoprostol
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2025-01-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05342974
The ClinicalTrials.gov registry entry for NCT05342974 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Misoprostol is the first listed.
NCT05342974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05342974 about?
NCT05342974 is a clinical study titled "Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy". Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-...
What is the current status of trial NCT05342974?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2022-04-19. Estimated completion is 2025-01-06.
What interventions are being tested in trial NCT05342974?
The interventions under investigation include: Misoprostol (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT05342974?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.